Healthy Skepticism Library item: 16387

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Electronic Source

Mack J
Full BOEHR(inger) Social Media Reporting of RELY Trial Results
Pharma Marketing Blog 2009 Aug 31
http://pharmamkting.blogspot.com/2009/08/full-boehringer-social-media-reporting.html

Full text:

Boehringer Ingelheim (BI’s) — the German pharmaceutical company — has just completed the first-ever full bore social media campaign touting the results of its RE-LY® study – “the largest atrial fibrillation (AF) outcomes trial ever conducted.” The results of the study were presented for the first time at the European Society of Cardiology (ESC) Congress yesterday. BI live-tweeted from the RELY press briefing and presentation in Barcelona.

The Tweets included statements like:

“RELY dabigatran had no liver toxicity” [Pradaxa® (dabigatran etexilate) is BI’s brand anti-coagulant drug that competes with generic warfarin]

“RE-LY results: Significance on primary endpoints and significantly lower bleeding”
PharmaGossip also reported that the word “Impressive” was used in a BI Tweet to describe the results and asked “Boehringer’s twittering at the ESC – is it being approved by their internal regulators?” This morning, I cannot find the @Boehringer Tweet PharmaGossip refers to — maybe BI deleted it — but the word “impressive” is used in the official press release. Therefore, I assume whatever is being posted on Twitter HAS been approved by BI’s regulatory/legal people.

BI also used Twitpic to show us that “Demand is high to get into the RELY press briefing” (see photo).

Not only has BI used the free services of Twitter and Twitpic to promote the results of this clinical trial, it also uploaded new videos on its new new Boehringer Stroke Prevention YouTube channel.

On August 27, 2009 it uploaded the video entitled “Day in the life of a Warfarin patient,” which has an actor portraying a patient who complains about the problems he has with warfarin treatment.

As promised, the YouTube channel is also “packed with RE-LY trial information.”

That’s a lot of promotion for very little money!

BI seems to be ahead of the pharma pack in using social media to woo journalists and physicians rather than the general public via Twitter and other social media. I discussed this strategy with Judith von Gordon, BI’s Head of External Communications, and John Pugh, BI’s Director of Corporate Communication/External Communications, in a June, 2009 Pharma Marketing Talk podcast (see “Boehringer Ingelheim Pharma on Twitter: Boehringer Ingelheim”).